Last updated 2026-06-18
- Raised $78M funding round led by Arboretum Ventures, Oct 2024
- Raised $30M funding round led by Bluestem Capital, Sep 2020
- Raised $13M funding round, Jun 2018
Total raised
$121.0M
Last: 2024-10
Stage
Series D
Founded
2015
Headcount
86
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide.
Orasis is led by a collaborative team of industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development.
Funding history · 5 rounds · $121.0M total
2024-10
2022-05
Undisclosed
2020-09
2018-06
2016-01
Undisclosed
Q&A
- What is Orasis Pharmaceuticals' primary product?
- Orasis Pharmaceuticals has developed QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, an FDA-approved prescription eye drop for presbyopia, which serves as an alternative to reading glasses.
- When was Orasis Pharmaceuticals founded?
- Orasis Pharmaceuticals was founded in September 2015.
- Where is Orasis Pharmaceuticals headquartered?
- Orasis Pharmaceuticals' headquarters are located in Herzliya, Israel, with an additional office in Ponte Vedra Beach, Florida, USA.
- How many employees does Orasis Pharmaceuticals have?
- Orasis Pharmaceuticals has 51-200 employees.
- What is the total amount of funding Orasis Pharmaceuticals has raised to date?
- Orasis Pharmaceuticals has raised a total of $121,000,000 USD.
- When did Orasis Pharmaceuticals complete its most recent funding round and who were the lead investors?
- In October 2024, Orasis Pharmaceuticals completed a funding round of $78,000,000 USD, led by.
- Which investors participated in Orasis Pharmaceuticals' September 2020 funding round?
- The September 2020 funding round for Orasis Pharmaceuticals, which raised $30,000,000 USD, was led by.
- What is the primary sector of Orasis Pharmaceuticals?
- Orasis Pharmaceuticals operates in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Who is the CEO of Orasis Pharmaceuticals?
- Elad Kedar is the CEO of Orasis Pharmaceuticals.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsophthalmologydrug-discoveryeye-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | orasis-pharma.com/ |
|---|---|
| linkedin.com/company/10476373 | |
| Wikidata | wikidata.org/wiki/Q30269240 |
Identifiers & details
| Founded | 2015-9 |
|---|---|
| Employees (exact) | 86 |
| Offices | Ponte Vedra Beach |
| Wikidata QID | Q30269240 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | orasis-pharma.com |
|---|
Wikidata
| QID | Q30269240 |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|